Cargando...
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Recent insights into the regulation of the androgen receptor (AR) activity led to novel therapeutic targeting of AR function in prostate cancer patients. Docetaxel is an approved chemotherapy for treatment of castration-resistant-prostate cancer (CRPC), but the mechanism underlying the action of thi...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2010
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2978028/ https://ncbi.nlm.nih.gov/pubmed/20807808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-0585 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|